2 news items
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer
CORT
HALO
MAIA
6 Jun 24
) is an investigational telomere-targeting agent designed to disrupt the survival mechanisms of cancer cells. By inducing telomerase-dependent DNA damage
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing's Syndrome)
CORT
28 May 24
they seek to help," said Rosario Pivonello, MD, PhD, Principal Investigator of the GRACE study and Professor of Endocrinology at Università Federico II di
- Prev
- 1
- Next